EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

Dkk-3, a Secreted Wnt Antagonist, Suppresses Tumorigenic Potential and Pulmonary Metastasis in Osteosarcoma

Carol H Lin, Yi Guo, Samia Ghaffar, Peter McQueen, Jonathan Pourmorady, Alexander Christ, Kevin Rooney, Tao Ji, Ramez Eskander, Xiaolin Zi, Bang H Hoang

Sarcoma · 2013 · 2013 · 1-11

DOI: 10.1155/2013/147541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoma, 2013. Verfasst von Carol H Lin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, CHOC Children's Hospital, 455 South Main Street, Orange, CA 92868, USA ; Department of Orthopaedic Surgery, University of Cal…. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: NCI NIH HHS, National Institutes of Health, American Cancer Society.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteosarcoma (OS) is the most common primary bone malignancy with a high propensity for local invasion and distant metastasis. Despite current multidisciplinary treatments, there has not been a drastic change in overall prognosis within the past 2 decades. Dickkopf-3 protein (Dkk-3/REIC) has been known to inhibit canonical Wnt/ β -catenin pathway, and its expression has been shown to be downregulated in OS cell lines. Using in vivo and in vitro studies, we demonstrated that Dkk-3-transfected 143B cells inhibited tumorigenesis and metastasis in an orthotopic xenograft model of OS. Inoculation of Dkk-3-transfected 143B cell lines into nude mice showed significant decreased tumor growth and less metastatic pulmonary nodules (88.7%) compared to the control vector. In vitro experiments examining cellular motility and viability demonstrated less anchorage-independent growth and decreased cellular motility for Dkk-3-transfected 143B and SaOS2 cell lines compared to the control vector. Downstream expressions of Met, MAPK, ALK, and S1004A were also downregulated in Dkk-3-transfected SaOS2 cells, suggesting the ability of Dkk-3 to inhibit tumorigenic potential of OS. Together, these data suggest that Dkk-3 has a negative impact on the progression of osteosarcoma. Reexpressing Dkk-3 in Dkk-3-deficient OS tumors may prove to be of benefit as a preventive or therapeutic strategy.

Autor:innen und Institutionen

  • Department of Oncology, CHOC Children's Hospital, 455 South Main Street, Orange, CA 92868, USA ; Department of Orthopaedic Surgery, University of California, Irvine, 101 The City Drive South, Orange, CA 92868, USA.

Förderung

  • NCI NIH HHS
  • National Institutes of Health
  • American Cancer Society
  • Orthopaedic Research and Education Foundation

Zitieren

APA

Lin, C. H., Guo, Y., Ghaffar, S., McQueen, P., Pourmorady, J., Christ, A., Rooney, K., Ji, T., Eskander, R., Zi, X., & Hoang, B. H. (2013). Dkk-3, a Secreted Wnt Antagonist, Suppresses Tumorigenic Potential and Pulmonary Metastasis in Osteosarcoma. Sarcoma, 2013, 1-11. https://doi.org/10.1155/2013/147541

Vancouver

Lin CH, Guo Y, Ghaffar S, McQueen P, Pourmorady J, Christ A, et al. Dkk-3, a Secreted Wnt Antagonist, Suppresses Tumorigenic Potential and Pulmonary Metastasis in Osteosarcoma. Sarcoma. 2013;2013:1-11. doi:10.1155/2013/147541

BibTeX
@article{Lin2013,
  author = {Lin, Carol H and Guo, Yi and Ghaffar, Samia and McQueen, Peter and Pourmorady, Jonathan and Christ, Alexander and Rooney, Kevin and Ji, Tao and Eskander, Ramez and Zi, Xiaolin and Hoang, Bang H},
  title = {Dkk-3, a Secreted Wnt Antagonist, Suppresses Tumorigenic Potential and Pulmonary Metastasis in Osteosarcoma},
  journal = {Sarcoma},
  year = {2013},
  volume = {2013},
  pages = {1--11},
  doi = {10.1155/2013/147541}
}
Kostenlos starten →